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INTRODUCTION
Tumor lysis syndrome (TLS) is a potentially life threatening 
complication of cancer treatments that typically occurs 
in highly proliferative malignancies. It is rare in patients 
with multiple myeloma  (MM) given the disease’s indolent 
nature and is estimated to occur in less than 1% of cases.1  
Increasing reports of TLS have been described in MM, 
particularly in treatment regimens containing bortezomib, 
the first available proteasome inhibitor.  Here we describe 
a case of a newly diagnosed light chain multiple myeloma 
resulting in tumor lysis syndrome following the first dose 
of combination therapy with bortezomib, cyclophos-
phamide and dexamethasone.
CASE REPORT
A 68 year old man presented with 6-8 weeks of gradually 
worsening lower back pain and fatigue. In addition, he 
reported symptoms of severe constipation, nausea, night 
sweats, dysuria, right sided rib pain, and a 30 lb weight 
loss. On examination, he had tenderness to palpation 
along the lower thoracic spine, para-spinal muscles 
and lower anterior ribs bilaterally.  He was found to 
have deranged renal function with a serum creatinine 
of 2.75 mg/dl, corrected serum calcium of 11.9 mg/dl, 
macrocytic anemia with hemoglobin of 11.4 g/dl  (MCV 
102) and urinalysis with trace protein but a urine protein 
to creatinine ratio of 9.6. The liver function tests were 
normal. An X-Ray of his thoracic and lumbar spine 
revealed a T12 compression fracture.
Subsequent labs revealed hypogammaglobulinemia and 
beta-2 microglobulin elevation of 19.53 mg/L (normal 
1.31-2.6 mg/L). Serum protein electrophoresis had a 
monoclonal lambda light chain spike measuring 14,520 
mg/L.  24 hour urine studies showed 11.5g of protein 
and 12.1g lambda light chains. A skeletal survey showed 
a questionable lucent lesion in the right 10th posterior 
rib. He underwent a bone marrow biopsy which showed 
45.9% plasma cells. FISH probe was negative for common 
cytogenetic abnormalities including 13q deletion. The 
patient was diagnosed with lambda light chain multiple 
myeloma, International Staging System (ISS) stage III.
For treatment, the day 1 cycle included bortezomib 
1.3mg/m2, cyclophosphamide 300mg, and dexamethasone 
40mg.  Prior to starting chemotherapy, his serum 
creatinine had improved to 2.5 mg/dL with normal serum 
electrolytes. Calcium remained elevated at 11.2mg/
dL despite hydration.  His care was transferred to the 
Veteran’s Hospital’s Community Living Center for the 
duration of his chemotherapy.
24 hours after his first dose of chemotherapy, he 
re-presented to the emergency room with hypoxia, 
hypotension, tachycardia, and tachypnea.  No fever 
was observed.  Initial laboratory values were as follows: 
potassium  5.5 mmol/L, serum uric acid 22.7 mg/dL, 
serum phosphorous 8.2mg/dL, bicarbonate 20mmol/L 
with anion gap of 17,  serum calcium 8.3mg/dL, lactate 
1.7mmol/L, LDH 1147 IU/L,  and serum creatinine 3.41 
mg/dL. He met clinical and laboratory criteria for tumor 
lysis syndrome (TLS) based on the Cairo-Bishop definition 
(Table 1). For TLS treatment the patient was started on 
IV fluid hydration with bicarbonate supplementation, 
allopurinol 200 mg daily and given a dose of raspuricase 
0.15 mg/kg. The patient was admitted to the ICU and 
closely monitored.
TABLE 1: CAIRO-BISHOP DEFINITION OF TUMOR LYSIS 
SYNDROME (TLS) IN ADULTS
Laboratory TLS:  ≥2 of the following serum 
abnormalities, developing within 3 days before or  
7 days after initiation of chemotherapy
  -Uric acid ≥ 8 mg/dL or 25% increase from baseline
  -Potassium ≥ 6 meq/L or 25% increase from baseline
  -Phosphorous ≥ 4.5 mmol/dL or 25% increase from   
   baseline
  -Calcium ≤ 7 mg/dL or 25% decrease from baseline
Clinical TLS: Laboratory TLS AND ≥1 of the 
following  criteria
  -Creatinine >1.5x upper limit of normal
  -Cardiac arrhythmia or sudden death
  -Seizure
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DIFFERENTIAL DIAGNOSIS
Differential diagnosis of new onset lower back pain in 
this elderly man included multiple myeloma, metastatic 
prostate cancer, lumbar strain, hyperparathyroidism 
and severe constipation secondary to an underlying 
malignancy of the colon.
OUTCOME AND FOLLOW UP
Over the course of several days, the patient’s TLS 
labs normalized and he was discharged back to the 
Veteran’s Community Living Center for rehabilitation. Per 
oncology’s recommendation, he was treated again with 
bortezomib, cyclophosphamide and dexamethasone.  He 
was re-admitted to the hospital approximately 2 weeks 
later with altered mental status and dehydration. Tumor 
lysis labs at this time were normal. During this hospital-
ization, the patient and his family made the decision to 
withhold further treatment and enter home hospice.
DISCUSSION
Tumor lysis syndrome (TLS) is a complication carrying a 
high morbidity and mortality most commonly occurring 
secondary to cell lysis caused by chemotherapy with the 
subsequent release of intracellular potassium, phosphate, 
and nucleic acids into the bloodstream.  Characteristic 
laboratory findings include hyperkalemia, hyperphos-
phatemia, hyperuricemia, hypocalcemia and elevated 
LDH.  Clinically, patients can present with nondescript 
symptoms such as nausea and vomiting, or life 
threatening cardiac arrhythmias, renal failure, seizures,or 
sudden death. TLS is most frequently associated with 
highly proliferative neoplasms such as non-Hodgkins 
lymphoma and acute lymphocytic leukemia,  while 
plasma cell dyscrasias such as multiple myeloma are 
classified as typically having a <1% risk.1 
Multiple myeloma is characterized by a low proliferative 
index with less than 1% plasma cells engaging in cellular 
proliferation.2 As a result, TLS is a rare complication of 
chemotherapy in the treatment of multiple myeloma. It 
is believed to have a higher likelihood of occurrence in 
patients with a high tumor burden, especially if treated 
with bortezomib in combination with other agents. The 
definition of high tumor cell burden is not clear in the 
literature, but it is believed to be correlated with increased 
serum lactate dehydrogenase and Beta-2 microglobulin 
levels (≥ 5.5 mg/dL)  as well as diffuse bone marrow 
disease, multiple lytic lesions, hypercalcemia (>12 mg/dL) 
and positive C reactive protein.8  TLS has also been cited 
to occur in monotherapy treatment with bortezomib, 
steroids, or thalidomide.2  Additional risk factors associated 
with the development of TLS in multiple myeloma 
include high proliferative activity, immature plasma cell 
morphology, and poor cytogenetics.2,3,4  Case reports by 
Hung Chang et al associate higher rates of TLS in light 
chain myeloma with pre-existing renal insufficiency prior 
to chemotherapy, a presentation similar to our patient. 
Nonetheless, not enough data exists to have clear 
understanding of the risk factors and whether certain 
types of multiple myeloma carry a higher risk.
Since the introduction of bortezomib, there have been 
several other case reports of patients with multiple 
myeloma developing tumor lysis syndrome with a 
reported incidence of 1.4%.3 As a reversible inhibitor of the 
26S proteasome, bortezomib’s impact on the transcrip-
tional factor NF-kB is thought to be the mechanism of 
rapidly induced cancer cell apoptosis.3 In a case series, 
Sezer et al. reviewed 496 cases of multiple myeloma 
treated with bortezomib in three phase II multi-center 
trials and found that the criteria for tumor lysis syndrome 
was fulfilled in 7 cases (1.8%). TLS caused renal failure 
leading to dialysis occurred in three cases, with one patient 
subsequently dying from renal failure. When a timeline 
was explicitly described, the earliest TLS case occurred 
on day 5 following bortezomib administration, making 
our patient’s presentation one day after treatment even 
more atypical.  Additionally, in two of the cases, TLS did 
not occur on initial exposure to bortezomib, but rather 
during retreatment with bortezomib in combination with 
dexamethasone.6 
Since the majority of reported cases of TLS typically occur 
very early in the course of treatment with bortezomib, 
patients are at the highest risk during the first cycle of 
therapy. Therefore, it is important to closely monitor 
patients receiving bortezomib, particularly those with 
higher tumor burden. Concomitant use of thalidomide 
or dexamethasone, such as in our patient, tends to 
increase the likelihood of tumor lysis syndrome.5  Chim 
in his article suggests TLS prophylaxis with hydration and 
alkalinization in patients with a high tumor burden who 
are being started on a treatment with bortezomib.
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CONCLUSION
Although rare, tumor lysis syndrome (TLS) is a potentially 
severe complication in the treatment of multiple 
myeloma. After initiation of treatment, patients should 
be closely monitored, particularly those with a high 
tumor burden receiving bortezomib. There is a need for 
further studies and case reports to identify incidence and 
predicting factors that may lead to TLS in patients treated 
for multiple myeloma.
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